Work

Abstract CT169: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct169

Authors: James M. Cleary, Carlos Gomez-Roca, Francois Ghiringhelli, Joon Oh Park, Tae-You Kim, Brandon Beagle, Janelle Soong, Yibing Yan, Hans-Joachim Helms, Janet Lau, Edward Cha, Michel Ducreux

Institutions: Dana-Farber Cancer Institute, Institut universitaire du cancer de Toulouse Oncopole, Université de Bourgogne, Genomic and Immunotherapy Medical Institute, Samsung Medical Center, Sungkyunkwan University, Seoul National University, Arcus Biosciences (United States), Roche (United Kingdom), Annexon Biosciences (United States), Instacart (United States), Roche (Switzerland), Institut Gustave Roussy

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822076

Cites:

Cited by:

Related to: 10